BOTANIX PHARMA LTD ORDINARY (BOT) Short Interest
BOTANIX PHARMA LTD ORDINARY (ASX:BOT) had 0.23% of shares reported as short positions as of 16 July 2026, representing 6,419,187 shares. BOTANIX PHARMA LTD ORDINARY operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Botanix Pharmaceuticals
Botanix Pharmaceuticals is an Australian clinical dermatology company focused on developing and commercializing innovative treatments for common skin diseases. Their lead product candidate is Sofdra, a potential treatment for primary axillary hyperhidrosis, and they are also developing other products for acne and atopic dermatitis.
Short position
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4BOT intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Botanix Pharmaceuticals
Latest BOT news
All news- Why is Botanix Pharmaceuticals (ASX:BOT) stock in focus today?
kalkine
- Top Botanix (ASX:BOT) Trend That Has ASX Cannabis Stocks Watching Closely
kalkine
- Botanix Pharmaceuticals (ASX:BOT) Leads a New ASX Penny Stocks Focus
kalkine
- Botanix Pharmaceuticals (ASX:BOT): Why This ASX Biotech Stock Is Catching Investor Attention - Kalkine
googlenews
- Why Is Botanix (ASX:BOT) Changing the Cannabis Stocks Test?
kalkine
About
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss BOT
Start a research thread or post the first pulse update